Repotrectinib: Why Did BMS Pay $4.1 Billion for Turning Point Therapeutics?
Drug Hunter Team

In 2022, Turning Point Therapeutics ($TPTX) was acquired by BMS for a whopping $4.1 billion in cash. In November 2023, the most advanced molecule from Turning Point, repotrectinib, was approved for the treatment of ROS1+ NSCLC. The molecule was selected as one of our 2021 Molecules of the Month before either the acquisition or approval.

This article explores the science behind repotrectinib, what properties make it valuable, how we know, and what's next.



Other articles you may be interested in